Drug and Alcohol Review

Cover image for Vol. 34 Issue 6

Edited By: Professor Robin Room

Impact Factor: 2.294

ISI Journal Citation Reports © Ranking: 2014: 9/35 (Substance Abuse (Social Science))

Online ISSN: 1465-3362

Author Guidelines


Drug and Alcohol Review is the official journal of the Australasian Professional Society on Alcohol and other Drugs (APSAD), and publishes independently refereed papers on clinical, biomedical, psychological and sociological aspects of alcohol, tobacco and drug use. Papers are accepted on the basis of the quality and originality of the research and its significance to our readership. Manuscripts are peer reviewed by at least two reviewers and the Editor. Final acceptance or rejection rests with the Editorial Board.

Manuscripts should be submitted online at http://mc.manuscriptcentral.com/dar and must adhere to the following guidelines.


Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author. Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.


Manuscripts are published in the following sections:

Original Papers – reports of new research findings or conceptual analyses that make a significant contribution to knowledge (3500 word limit). Papers analysing qualitative fieldwork or documentary materials (normally without tables) may have up to 4500 words.

Commentaries– evidence-based opinion pieces involving areas of broad interest (1500 word limit) and invited commentaries (1000 word limit).

Comprehensive Reviews – critical reviews of the literature, including systematic reviews and meta-analyses (5000 word limit).

Brief Reports- preliminary findings of research in progress or a case report of particular interest (1500 word limit).

Editorial articles– are usually commissioned but unsolicited material may be considered. Please approach the Editor-in-Chief before submitting this material (Email to: dar@apsad.org.au).

Letters to the Editor– are welcomed and will be published online only (1000 word limit).

Critiques– reviews of books or grey literature (please approach the Critiques Editor before submitting a review, 800 word limit).

Special Issues and Special Sections on topics of interest are also regularly published


1. Cover Letter
• The International Society of Addiction Journal Editors (ISAJE) Guidelines define authorship as substantial contribution to all aspects of the research design, analysis and interpretation of data and contribution to the intellectual content of the article. All authors must acknowledge these guidelines and be willing to take public responsibility for the content of the article.
• Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere. This must be stated in the cover letter.
• Authors must declare any financial support or relationships that may pose conflict of interest.
• If tables or figures have been reproduced from another source, a letter from the copyright holder (usually the publisher), stating authorisation to reproduce the material, must be attached to the cover letter.

2. Ethical Considerations
ISAJE Ethical Practice Guidelines provide guidance to authors ‘regarding ethical and procedural issues that affect the integrity of scientific publishing’. We ask that authors read and observe these guidelines especially in regard to study design and ethical approval, consent, authorship, conflict of interests, plagiarism and redundant publication.
• Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004) available here.

3. Registration
All randomised controlled trials (RCTs) must be registered with a public trials registry such as the Australian and New Zealand Clinical Trials Register (ANZCTR). Trial registration number and name of the registry will need to be cited in the acknowledgement section of the paper. If the commencement of the trial precedes the registration date, please explain why in the cover letter.

4. Reporting Guidelines
• RCTs: The CONSORT Statement provides evidence based recommendations for reporting RCTs. All RCTs must follow the CONSORT guidelines including the checklist and flow diagram.
• Reviews: The PRISMA Statement encourages transparent reporting of meta-analyses and systematic reviews. The PRISMA checklist and flow diagram should be included. To view the PRISMA Statement and Guidelines click here.
• Case-Controlled, Cohort, Cross-Sectional Studies: Refer to the STROBE Statement and checklist for reporting.

5. Manuscript Parts
Manuscripts should be presented in the following order:
(a) Title page
(b) Abstract and key words
(c) Text
(d) Acknowledgements
(e) References
(f) Appendices
(g) Figures
(h) Tables
(i) An ethics statement must be included in the Methods section.
Footnotes to the text will not be published and any such material should be incorporated into the text as parenthetical matter.

(a) Title page
The title page should contain:
1. The title of the paper – the title should be concise and informative, with no abbreviations
2. A short running title of no more than 40 characters
3. The full names, academic qualifications (e.g. BA, MSc, PhD etc.) and job position titles of the authors
4. The name of department(s) and institution(s) at which the work was carried out
5. The full postal and email address, plus facsimile and telephone numbers, of the corresponding author.

(b) Abstract and key words
The second page should carry a structured abstract of not more than 250 words, using the following headings:
• For Original Papers - Introduction and Aims, Design and Methods, Results, Discussion and Conclusions
• For Reviews - Issues, Approach, Key Findings, Implications, Conclusion
• Abstracts may be included but are not required for Harm Reduction Digests, Asia Pacific Columns, Brief Reports and Commentaries.

For the purposes of indexing, five key words, should be supplied below the abstract and should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list.

(c) Text
The text of Original Papers should conform to the conventional structure for biomedical communications - introduction, methods, results and discussion. The format of Reviews and Commentaries is likely to differ from this and authors should consult previous issues of the Journal for guidance. Brief Reports should generally conform to the format of original papers. All results should be justified by describing the statistical methods employed and the results of the tests of statistical significance.

We suggest authors follow guidelines for the discussion section of their paper, as reported in the British Medical Journal (abstract): (Docherty BMJ 1999)
• Statement of principal findings
• Strengths and weaknesses of the study
• Strengths and weaknesses in relation to other studies, discussing particularly any differences in results
• Meaning of the study: possible mechanisms and implications for clinicians or policymakers
• Unanswered questions and future research

(d) Acknowledgements
All sources of support in the form of financial grants, equipment or drugs should be stated in the acknowledgement section. Contributions of colleagues or institutions can be acknowledged but personal thanks or appreciation of anonymous reviewers is not appropriate. Trial registration number and name of the public trial registry should be listed here for an RCT.

(e) References
The Vancouver system of referencing should be used. References should be numbered consecutively in the order in which they are first mentioned in the text. Indicate in the text with Arabic numbers inside square brackets (e.g. [1] or [2-7] or [4, 5]). If cited in tables or figure legends, number according to the first identification of the table or figure in the text. In the reference list, cite the names of all authors. Avoid the use of unpublished abstracts as references. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2011, unpublished data). Manuscripts accepted but not yet published may be referenced, the journal should be named and the phrase ‘(in press)’ should follow. All citations mentioned in the text, tables or figures must be listed in the reference list.

We recommend the use of software such as Reference Manager for reference management and formatting.

References should be formatted as follows:

ournal articles
[1] Rose G. International trends in cardiovascular disease: implications for prevention and treatment. Aust NZJ Med 2005;14:375-80.
[2] Smith AD, Phillips M, Gillis BZ, et al. Drugs and their impact on society. Br J Psychiatry 2006;80:415-17.

[3] Henderson S, Byrne DG, Duncan-Jones P. Neurosis and the social environment, 3rd edn. Sydney: Academic Press, 1981.

Book Chapter
[4] Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman WA Jr, Sodeman WA, eds. Pathologic physiology: mechanisms of disease. Philadelphia: WB Saunders, 1999:457-72.

[5] Oxford Centre for Evidence-based Medicine. Levels of Evidence (March 2009). Available at: http://www.cebm.net/index.aspx?o=1025 (accessed November 2011).

(f) Tables
Tables should be self-contained and complement, not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Explanatory matter, including definition of abbreviations, should be placed in footnotes. Type tables on a separate page with the legend above; legends should be concise but comprehensive - the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses. If data come from another published or unpublished paper, the original source should be cited.

(g) Figures
All illustrations (line drawings and photographs) are classified as figures. There is a maximum of five (5) tables and figures (combined) per manuscript. If a paper requires more than this, the author(s) should provide justification in their cover letter.

Figures should be cited in consecutive order in the text. Figures should be sized to fit within the column (82 mm), intermediate (120 mm) or the full text width (172 mm). Magnifications should be indicated using a scale bar on the illustration.

Each figure should be supplied as a separate file, with the figure number incorporated in the file name. High-resolution figures (at least 300 dpi) saved as .eps or .tif files should be uploaded. Digital images supplied only as low-resolution files cannot be used.

Line figures should be sharp, black and white graphs or diagrams, drawn professionally or with a computer graphics package. Lettering must be included and should be no larger than the journal text.

Type figure legends on a separate page. Legends should be concise but comprehensive - the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

(h) Supporting information
Supporting information that is not essential to the article but provides greater depth and background may be submitted with the manuscript. Material such as data sets, additional figures or tables, or computer code that will not be published in the print edition of the Journal but which will be viewable in the online edition may be submitted.

Supporting material will be published exactly as supplied and it is the author’s responsibility to ensure that the material is logically laid out, adequately described and is in a format that is likely to be accessible to readers. Guidelines for preparation of this material are available at: http://authorservices.wiley.com/bauthor/suppmat.asp

6. Manuscript Style
We encourage high quality writing and refer our authors to one of the many writing guides available online such as Kipling’s Guide to Writing a Scientific Paper. Manuscripts should follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors' revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication.

Manuscripts are submitted online in Word, double spaced, page number in top right-hand corner, do not use ‘Enter’ at the end of lines within a paragraph.
• Spelling: The Journal uses English (UK) spelling.
• Units: All measurements must be given in SI or SI-derived units with traditional units in parentheses; exceptions are blood pressure which should be expressed in mm Hg and haemoglobin concentration (g/dl).
• Abbreviations: An explanation of all abbreviations should be given on the first occasion of their use, with the exception of abbreviations of certain standard units of measurement and statistical measures of variation such as SD and SEM which may be used without explanation.
• Trade names: Drugs should be given their approved, not proprietary, names and the source of any new or experimental preparation should be given.

7. Copyright
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be viewed here: Link to PDF

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.htm


A paper published in Drug and Alcohol Review will be permanently available by subscription or purchase on the Wiley web pages. Authors can also make their paper freely available on the Drug and Alcohol Review website through open access (see OnlineOpen below). Authors may post an electronic version of their article on their own personal website, their employer’s website/repository or on free public servers in their subject area 12 months after publication. Electronic versions of the accepted article must include a link to the published version of the article, together with the following text: “The definitive version is available at www.onlinelibrary.wiley.com”. For papers supported by an Australian funding agency which requires open access publication, the paper will be made available by open access on the Wiley site within 12 months of publication. For US NIH funded research and other funding bodies please refer to Wiley’s open access policy: http://olabout.wiley.com/WileyCDA/Section/id-406074.html


Visit the Drug and Alcohol Review website and Wiley's web pages for submission guidelines and digital graphic standards. Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status and choose to receive automated emails at key stages of production. Click here for more details on online production tracking and other resources.

Drug and Alcohol Reviewis covered by our EarlyView service. EarlyView articles are complete full-text articles published online in advance of their print publication. EarlyView articles are complete and final. No changes can be made after online publication. However, EarlyView articles do not yet have volume, issue or page numbers so cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), so the article can be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found here.

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee (currently US$3000) to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://olabout.wiley.com/WileyCDA/Section/id-406241.html.
The OnlineOpen option is offered only to those authors whose articles have been accepted for publication, and only at the point when the article is accepted, to ensure that the OnlineOpen option has no influence on the peer review and acceptance process. Prior to acceptance you should not inform the editorial office that you intend to publish your paper OnlineOpen. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.


Corresponding authors must supply an active email address while their article is in production. Notification of the URL for the PDF typeset page proof, associated forms and further instructions will be sent by email. The purpose of the PDF proof is a final check of the layout, and of tables and figures. Alterations other than the essential correction of errors cannot be accepted at PDF proof stage. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated, otherwise, it may be signed off on by the Editor or held over to the next issue.


In order to receive an email alert when your article has been published online and to access the free PDF offprint, please register with Wiley's Author Services at: http://authorservices.wiley.com/bauthor/register.asp. Paper offprints may be ordered online at http://offprint. cosprinters.com/. If you have queries about offprints, please email offprint@cosprinters.com


Editorial Officer
Drug and Alcohol Review
PO Box R1014, Royal Exchange
NSW 1225
Tel.: +61(0)2 9252 2281
Email: dar@apsad.org.au